Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02817906 · ClinicalTrials.gov registry record · Phase 3
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
A Phase 3 study, sponsored by Intra-Cellular Therapies.
- Terminated
- Registry status
- Phase 3
- Development phase
- 177
- Enrollment target
NCT02817906 is a Phase 3 study that was terminated before completion, run by Intra-Cellular Therapies. The registered enrollment target is 177 participants.
The verdict
NCT02817906, a Phase 3 study, was terminated before completion, sponsored by Intra-Cellular Therapies.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 177 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG ITI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2016-08-29 |
| Est. Completion | 2019-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02817906
The ClinicalTrials.gov registry entry for NCT02817906 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intra-Cellular Therapies, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02817906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02817906 about?
NCT02817906 is a clinical study titled "ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease". This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including Alzheimer's disease.
What is the current status of trial NCT02817906?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 177 participants. The study started on 2016-08-29. Estimated completion is 2019-01-30.
What interventions are being tested in trial NCT02817906?
The interventions under investigation include: Placebo (DRUG), ITI-007 (DRUG).
Who is sponsoring clinical trial NCT02817906?
This trial is sponsored by Intra-Cellular Therapies, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.